Immune checkpoint blockade in hematologic malignancies

被引：205

作者：

Armand, Philippe ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

来源：

BLOOD | 2015年 / 125卷 / 22期

关键词：

B-CELL LYMPHOMA; DEATH-LIGAND; T-CELLS; FOLLICULAR LYMPHOMA; ANTI-PD-L1; ANTIBODY; HODGKIN LYMPHOMAS; ADVANCED MELANOMA; MULTIPLE-MYELOMA; PD-1; BLOCKADE; EXPRESSION;

D O I：

10.1182/blood-2015-02-567453

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Therapeutic blockade of immune checkpoint pathways, in particular cytotoxic T-lymphocyte associated protein 4 and programmed-death 1 (PD-1), has become a paradigm-shifting treatment in solid tumor oncology. Hematologic malignancies (HMs), many of which are known to have clinically exploitable immune sensitivity, are a natural target for this type of treatment. Several clinical trials of checkpoint blockade have been conducted in HM, with preliminary results suggesting the therapeutic usefulness of this approach across several tumor types. In particular, the results of PD-1 blockade in Hodgkin lymphoma (HL) are remarkable, and raise hope that it may alter the treatment landscape in this disease. However, numerous questions remain about the optimal role of checkpoint blockade both in HL and beyond. Those questions are the focus of this review, in the hope that, if we are at the dawn of a new day in HM immunotherapy, we may begin to envision its morning.

引用

页码：3393 / 3400

页数：8

共 71 条

[1] Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells [J].

Andorsky, David J. ;

Yamada, Reiko E. ;

Said, Jonathan ;

Pinkus, Geraldine S. ;

Betting, David J. ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2011, 17 (13) :4232-4244

[2]

[Anonymous], BLOOD

[3]

AnselL S., 2013, J IMMUNOTHER CANC S1, V1, pP259, DOI DOI 10.1186/2051-1426-1-S1-P259

[4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[5] Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].

Ansell, Stephen M. ;

Hurvitz, Sara A. ;

Koenig, Patricia A. ;

LaPlant, Betsy R. ;

Kabat, Brian F. ;

Fernando, Donna ;

Habermann, Thomas M. ;

Inwards, David J. ;

Verma, Meena ;

Yamada, Reiko ;

Erlichman, Charles ;

Lowy, Israel ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453

[6] Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].

Armand, Philippe ;

Nagler, Arnon ;

Weller, Edie A. ;

Devine, Steven M. ;

Avigan, David E. ;

Chen, Yi-Bin ;

Kaminski, Mark S. ;

Holland, H. Kent ;

Winter, Jane N. ;

Mason, James R. ;

Fay, Joseph W. ;

Rizzieri, David A. ;

Hosing, Chitra M. ;

Ball, Edward D. ;

Uberti, Joseph P. ;

Lazarus, Hillard M. ;

Mapara, Markus Y. ;

Gregory, Stephanie A. ;

Timmerman, John M. ;

Andorsky, David ;

Or, Reuven ;

Waller, Edmund K. ;

Rotem-Yehudar, Rinat ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206

[7] Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era [J].

Armand, Philippe ;

Welch, Sarah ;

Kim, Haesook T. ;

LaCasce, Ann S. ;

Jacobsen, Eric D. ;

Davids, Matthew S. ;

Jacobson, Caron ;

Fisher, David C. ;

Brown, Jennifer R. ;

Coughlin, Erin ;

Freedman, Arnold S. ;

Chen, Yi-Bin .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (05) :608-617

[8] Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion [J].

Bachireddy, Pavan ;

Hainz, Ursula ;

Rooney, Michael ;

Pozdnyakova, Olga ;

Aldridge, Julie ;

Zhang, Wandi ;

Liao, Xiaoyun ;

Hodi, F. Stephen ;

O'Connell, Karyn ;

Haining, W. Nicholas ;

Goldstein, Natalie R. ;

Canning, Christine M. ;

Soiffer, Robert J. ;

Ritz, Jerome ;

Hacohen, Nir ;

Alyea, Edwin P., III ;

Kim, Haesook T. ;

Wu, Catherine J. .

BLOOD, 2014, 123 (09) :1412-1421

[9] CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[10] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

← 1 2 3 4 5 6 7 8 →